How CRISPR Diagnostics Could Transform Infectious Disease Testing

Lucas and Luna explore the emerging field of CRISPR-based diagnostics, which uses gene-editing tools to detect infectious diseases like COVID-19, dengue, and tuberculosis with rapid, low-cost tests. They focus on a 2025 study from the Broad Institute showing a CRISPR assay that detects SARS-CoV-2 in under 30 minutes with 98% sensitivity, compared to PCR's 95% but with lab delays. The hosts discuss the startup Sherlock Biosciences, founded by CRISPR pioneer Feng Zhang, which is commercializing these tests for point-of-care use. They also examine regulatory hurdles, manufacturing challenges, and the potential to transform outbreak response in low-resource settings. The episode draws a clear contrast with traditional PCR and rapid antigen tests, showing where CRISPR diagnostics fit in the testing landscape. #CRISPR #Diagnostics #InfectiousDisease #SherlockBiosciences #FengZhang #BroadInstitute #PointOfCare #COVID19 #Dengue #Tuberculosis #PCR #RapidTests #Biotech #Startups #FDA #GeneEditing #FexingoBusiness #BusinessPodcast Keep every episode free: buymeacoffee.com/fexingo